+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes

Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes

Experimental Gerontology 46(4): 217-224

A non-enzymatic reaction between ketones or aldehydes and the amino groups of proteins, lipids and nucleic acids contributes to the aging of macromolecules and to the development and progression of various age-related disorders such as vascular complications of diabetes, Alzheimer's disease, cancer growth and metastasis, insulin resistance and degenerative bone disease. Under hyperglycemic and/or oxidative stress conditions, this process begins with the conversion of reversible Schiff base adducts, and then to more stable, covalently-bound Amadori rearrangement products. Over a course of days to weeks, these early glycation products undergo further reactions and rearrangements to become irreversibly crossed-linked, fluorescent protein derivatives termed advanced glycation end products (AGEs). There is a growing body of evidence that AGE and their receptor RAGE (receptor for AGEs) interaction elicits oxidative stress, inflammatory reactions and thrombosis, thereby being involved in vascular aging and damage. These observations suggest that the AGE-RAGE system is a novel therapeutic target for preventing diabetic vascular complications. In this paper, we review the pathophysiological role of the AGE-RAGE-oxidative stress system and its therapeutic intervention in vascular damage in diabetes. We also discuss here the potential utility of the restriction of food-derived AGEs in diabetic vascular complications.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 055600553

Download citation: RISBibTeXText

PMID: 21111800

DOI: 10.1016/j.exger.2010.11.007

Related references

Glycolaldehyde-derived advanced glycation end products (glycol-AGEs)-induced vascular smooth muscle cell dysfunction is regulated by the AGES-receptor (RAGE) axis in endothelium. Cell Communication and Adhesion 22(2-6): 67-78, 2016

New metabolic marker: Advanced glycation end products (AGEs) and receptor for advanced glycation end products (RAGE) system may play a role in the pathogenesis of recurrent pregnancy losses. Journal of Reproductive Immunology 106: 10-11, 2014

Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvascular Research 75(1): 130-134, 2008

Irbesartan attenuates advanced glycation end products-mediated damage in diabetes-associated osteoporosis through the AGEs/RAGE pathway. Life Sciences 205: 184-192, 2018

Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level. Metabolism: Clinical and Experimental 61(8): 1067-1072, 2012

Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. International Journal of Clinical Pharmacology Research 23(4): 129-134, 2003

Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression. Hormone and Metabolic Research 44(12): 891-895, 2013

Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovascular Diabetology 14: 2, 2015

Curcumin inhibits advanced glycation end-products AGEs-induced gene expression of receptor for AGEs RAGE in hepatic stellate cells in vitro by elevating PPAR? activity and attenuating oxidative stress. 2012

Blockade of the advanced glycation end products (AGEs) and their receptor (RAGE) system is a possible mechanism for sustained beneficial effects of multifactorial intervention on mortality in type 2 diabetes. Medical Hypotheses 71(5): 749-751, 2008

AGEs and RAGE - advanced glycation end-products and their receptor in questions and answers. Vnitrni Lekarstvi 60(9): 720-724, 2014

Advanced glycation end products (AGEs) and their receptor (RAGE) in health and disease. Current Pharmaceutical Design 14(10): 939, 2008

Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochimica et Biophysica Acta 1820(5): 663-671, 2012

Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy. Current Drug Discovery Technologies 3(1): 83-88, 2006

Advanced Glycation End Products (Ages) and their Receptor (Rage) System in Diabetic Retinopathy. Current Drug Discovery Technologies 3(1): 83-88, 2006